Gene fusion
A gene fusion is two genes broken and joined together, creating a hybrid protein that can drive cancer. Fusion-driven cancers are often exquisitely drug-sensitive.
EML4-ALK, ROS1, RET, NTRK, FGFR2, NRG1, BCR-ABL. Best detected by RNA sequencing. Fusions define tumour-agnostic indications (NTRK, RET) and are the archetype of oncogene addiction.
Pages like this
not linked directly; found by shared links- TargetROS1
Shares Taletrectinib, University of Colorado Cancer Center, Crizotinib, Entrectinib.
- TermTumour-agnostic (tissue-agnostic) approval
Shares A standard for tumour-agnostic approvals: minimum histologies and hierarchical modelling, Driver mutation (actionable / targetable alteration), Larotrectinib, Entrectinib.
- TermOncogene addiction
Shares Driver mutation (actionable / targetable alteration), University of Colorado Cancer Center, Crizotinib, CROWN: lorlatinib versus crizotinib as first treatment for ALK-positive lung cancer.
- ProductLorlatinib
Shares University of Colorado Cancer Center, CROWN: lorlatinib versus crizotinib as first treatment for ALK-positive lung cancer, Develop drugs in children first when the target is a children's target, ALK.
- ProductImatinib
Shares Chromosome, Sarcoma (tissue type), Philadelphia chromosome (Ph+, BCR::ABL1), Janet Rowley.
- ProductPemigatinib
Shares FGFR2 fusions and rearrangements, FGFR2, Biliary tract cancer (cholangiocarcinoma).
- ProductFutibatinib
Shares FGFR2 fusions and rearrangements, FGFR2, Biliary tract cancer (cholangiocarcinoma).
- IdeactDNA-guided switching among FGFR inhibitors
Shares FGFR2 fusions and rearrangements, FGFR2, Biliary tract cancer (cholangiocarcinoma).